Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

ABSTRACT: Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

PROVIDER: PRJNA951444 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24044207_1.fastq.gz	Fastqsanger.gz
	SRR24044207_2.fastq.gz	Fastqsanger.gz
	SRR24044208_1.fastq.gz	Fastqsanger.gz
	SRR24044208_2.fastq.gz	Fastqsanger.gz
	SRR24044209_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 39

Similar Datasets

Epigenetic regulation of NK cell-mediated immune response in multiple myeloma [RNA-Seq]

Project description:Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we performed two in vitro genome-wide CRISPR screens to systematically discover the regulators of sensitivity to Dara-mediated antibody-dependent cellular cytotoxicity (ADCC) and identified KDM6A. The loss of KDM6A led to a marked downregulation in CD38 expression by increasing H3K27me3 on the CD38 promoter, resulting in resistance to Dara-mediated ADCC. Yet, adding back CD38 did not completely rescue this phenotype. In fact, KDM6A loss also downregulated CD48, which promoted Dara resistance by inhibiting natural killer cell activity. Lowering the H3K27me3 with an EZH2 inhibitor restored sensitivity to Dara through CD38 and CD48 upregulation. These findings suggest KDM6A loss as a mechanism of Dara resistance and explore the strategy of using an EZH2 inhibitor, one of which is already FDA-approved, to improve the response to Dara in MM.

2024-01-23 | GSE228769 | GEO

Epigenetic regulation of NK cell-mediated immune response in multiple myeloma [ChIP-Seq]

2024-01-23 | GSE228768 | GEO

Epigenetic regulation of NK cell-mediated immune response in multiple myeloma [ATAC-Seq]

2024-01-23 | GSE228766 | GEO

Epigenetic regulation of NK cell-mediated immune response in multiple myeloma [CRISPR screening 2]

2024-01-23 | GSE228770 | GEO

Epigenetic regulation of NK cell-mediated immune response in multiple myeloma [CRISPR screening 1]

2024-01-23 | GSE228767 | GEO

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-01-22 | GSE228771 | GEO

Human Innate Lymphoid Cell Precursors Express CD48 that Modulates ILC Differentiation through 2B4 Signaling

Project description:Innate lymphoid cells (ILCs) develop from common lymphoid progenitors (CLP), which further differentiate into the common ILC progenitor (CILP) that can give rise to both ILCs and NK cells. Murine ILC intermediates have recently been characterized, but the human counterparts and their developmental trajectories have not yet been identified, largely due to the lack of homologous surface receptors in both organisms. Here, we show that human CILPs (CD34+CD117+α4β7+Lin-) acquire CD48 and CD52, which define NK progenitors (NKPs) and innate lymphoid cell precursors (ILCPs). Two distinct NK cell subsets were generated in vitro from CD34+CD117+α4β7+Lin-CD48-CD52+ and CD34+CD117+α4β7+Lin-CD48+CD52+ NKPs, respectively. Independent of NKPs, ILCPs exist in the CD34+CD117+α4β7+Lin-CD48+CD52+ subset and give rise to ILC1s, ILC2s and NCR+ ILC3s, whereas CD34+CD117+α4β7+Lin-CD48+CD52- ILCPs give rise to a distinct subset of ILC3s that have lymphoid tissue inducer (LTi)-like properties. Additionally, CD48 expressing CD34+CD117+α4β7+Lin- precursors give rise to tissue-associated ILCs in vivo. We also observed that the interaction of 2B4 with CD48 induced differentiation of ILC2s, and together these findings show that expression of CD48 by human ILCPs modulates ILC differentiation.

2020-11-20 | GSE160009 | GEO

KDM6A Regulates Immunogenicity of Multiple Myeloma (ChIP-seq)

Project description:We created isogenic mutiple myeloma and mouse embryonic fibroblast cell lines disrupted for KDM6A using CRISPR editing and Cre-mediated deletion. To detect KDM6A we inserted a dual HA tag sequence into the C-terminal of KDM6A by CRISPR-mediated editing. We also created one isogenic cell line harboring a jmjD-dead KDM6A where 2 amino acids essential for KDM6A enzymatic activity, H1146 and E1148 , were replaced with alanine residues

2024-10-01 | GSE244510 | GEO

KDM6A Regulates Immunogenicity of Multiple Myeloma (ATAC-seq)

Project description:We created isogenic mutiple myeloma cell lines disrupted for KDM6A using CRISPR-mediated editing.

2024-10-01 | GSE244509 | GEO

KDM6A Regulates Immunogenicity of Multiple Myeloma (RNA-seq)

Project description:We created isogenic mutiple myeloma and mouse embryonic fibroblast cell lines disrupted for KDM6A using CRISPR editing and Cre-mediated deletion.

2024-10-01 | GSE244511 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data